Clinical Characteristics and Time to Onset of JAK-Inhibitor-Associated Acne: A Retrospective Chart Review…

Cohort studyJournal of drugs in dermatology : JDD· Aug 2026

Clinical Characteristics and Time to Onset of JAK-Inhibitor-Associated Acne: A Retrospective Chart Review Study.

Alexandra Nigro, Lara Shqair, Isabel C Silva, Saakshi Khattri

Read paper

Acne & RosaceaCohort studyClinical practiceQ2IF 1.7

Janus kinase-inhibitor-associated acne appeared at a median of 91 days after starting therapy.

Clinical Characteristics and Time to Onset of JAK-Inhibitor-Associated Acne: A Retrospective Chart Review Study.

Alexandra Nigro … Saakshi Khattri

Journal of drugs in dermatology · Aug 2026 · Q2 in Dermatology

Background

Acne is a common cutaneous adverse event associated with Janus kinase (janus kinase) inhibitors, with incidence varying across agents.

Purpose

This paper aims to characterize the demographic features, timing, and clinical presentation of acne associated with oral janus kinase inhibitor therapy across multiple agents.

Methods

We conducted a retrospective chart review of patients treated at Mount Sinai Dermatology who were prescribed oral janus kinase inhibitors (tofacitinib, baricitinib, upadacitinib, abrocitinib, or ritlecitinib) and had a documented diagnosis of acne.

n = Fifty-seven (57) patients

Results

acne surfaced roughly three months after starting a janus kinase inhibitor, not immediately

Upadacitinib

72%

Tofacitinib

11%

Baricitinib

7%

Abrocitinib

5%

More results

Fifty-seven (57) patients developed acne while receiving janus kinase inhibitors.

The cohort was predominantly female (70%) and White (53%), with a mean age of 34.2 ± 13.2 years.

Upadacitinib was the most frequently implicated agent (72%), followed by tofacitinib (11%), baricitinib (7%), abrocitinib (5%), and ritlecitinib (5%).

“

Conclusion · 1 of 2

Acne is an increasingly observed dermatologic adverse event in patients treated with janus kinase inhibitors.

Conclusion · 2 of 2

This study further characterizes the timing and clinical presentation of janus kinase-induced acne and may enhance patient counseling, clinical monitoring, and management strategies as janus kinase inhibitor use continues to expand. &nbsp.

Clinical Characteristics and Time to Onset of JAK-Inhibitor-Associated Acne: A Retrospective Chart Review Study.

Clinical Characteristics and Time to Onset of JAK-Inhibitor-Associated Acne: A Retrospective Chart Review Study.

Related papers